What is Quantum Computing?

February 21, 2019 Aysha Naurein 0

What is Quantum Computing? By: Aysha Naurein Computers have today become so common that it would be difficult for us to think of a life devoid of them. It helps us do a lot of work simultaneously, quickly, effectively and has made life a lot easier. There are better versions [..]

AI, the Law, and Our Future

January 23, 2019 Scipreneur Private Limited 0

AI, the Law, and Our Future By: Peter Dizikes | MIT News Office Scientists and policymakers converged at MIT on Tuesday to discuss one of the hardest problems in artificial intelligence: How to govern it. The first MIT AI Policy Congress featured seven panel discussions sprawling across a variety of [..]

FDA Approved Firdapse® :First  Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)

December 5, 2018 Scipreneur Private Limited 0

FDA Approved Firdapse® :First  Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) By: Catalyst Pharmaceuticals, Inc. NEWS Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved Firdapse® [..]

Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease

November 23, 2018 Scipreneur Private Limited 0

Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease By: Novartis News Novartis announced today that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both [..]

FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia

November 22, 2018 Scipreneur Private Limited 0

FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Venclexta® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or [..]

FDA Approves Novartis Drug Promacta® for First-line SAA |Breakthrough Therapy Designation

November 16, 2018 Scipreneur Private Limited 0

FDA Approves Novartis Drug Promacta® for First-line SAA |Breakthrough Therapy Designation By: Novartis News Basel, November 16, 2018 – Novartis announced today that the US Food and Drug Administration (FDA) has expanded the label for Promacta®(eltrombopag) to include first-line treatment for adults and pediatric patients two years and older with SAA in [..]

Sandoz Receives FDA Approval for Biosimilar HyrimozTM

October 31, 2018 Scipreneur Private Limited 0

Sandoz Receives FDA Approval for Biosimilar HyrimozTM By: Novartis News Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients [..]

National Fellowships for Graduates/Post Graduates Students, India :2

October 25, 2018 Richa 0

National Fellowships for Graduates/Post Graduates Students, India :2 By: Dr. Richa Lakhotia Here is the remaining list of all other fellowships.  14. Postdoctoral Fellowships in Physics at Harish-Chandra Research Institute in India, 2018 The Harish-Chandra Research Institute is delighted to offer its postdoctoral fellowships in Physics for Indian students. The fellowships [..]

National Fellowships for Graduates/Post Graduates Students, India :1

October 23, 2018 Richa 0

National Fellowships for Graduates/Post Graduates Students, India | TOC 1 By: Dr. Richa Lakhotia There are many exciting programs and funding opportunities to support graduates/post graduates students in India. Check out these fellowships available for indian students with varying academic backgrounds.  (1) Extra Mural Research Funding (Individual Centric) Individual centric competitive mode of [..]

Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer

September 30, 2018 Scipreneur Private Limited 0

Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery [..]

FDA Approved the First and Only Therapy for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease

September 30, 2018 Scipreneur Private Limited 0

FDA Approved the First and Only Therapy for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ARIKAYCE® (amikacin liposome inhalation suspension) for the [..]

FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease

August 10, 2018 Scipreneur Private Limited 0

FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease By: Alnylam News Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment [..]

EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana

EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration [..]

FDA Approves TPOXX® :The First Drug For Smallpox

FDA Approves TPOXX® :The First Drug For Smallpox SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule [..]

Tafinlar® + Mekinist® of Novartis Receives FDA Approval for the Treatment of BRAF V600-Mutant Melanoma

Tafinlar® + Mekinist® of Novartis Receives FDA Approval for the Treatment of BRAF V600-Mutant Melanoma By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as [..]

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

March 21, 2018 Scipreneur Private Limited 0

Novartis teams up with Harvard to develop next-generation biomaterial systems to deliver immunotherapies By: Novartis News Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of [..]

U.S. FDA Approved ERLEADA™ for Prostate Cancer

February 28, 2018 Scipreneur Private Limited 0

U.S. FDA Approved ERLEADA™ for Prostate Cancer By: Janssen News The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved ERLEADA™ (apalutamide), a next-generation androgen receptor inhibitor,[1] for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). ERLEADA™ is the first FDA-approved [..]